Eurofins Scientific faces significant stock market penalties due to disappointing growth, particularly in biopharmaceutical services, leading to a lowered revenue forecast for 2024. The company reported third-quarter revenues of 1.72 billion euros, falling short of expectations, with organic growth at just 4.4%. An independent audit confirmed the integrity of its cash accounting practices, countering allegations of financial misconduct.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.